Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression

• Published in: Oncotarget Vol. 8; no. 61; pp. 103410 - 103414
• Main Authors: Guo, Liyuan, Peng, Yan, Sun, Lei, Han, Xia, Xu, Juan, Mao, Dongwei
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 28-11-2017
• Subjects: Research Paper; ovarian cancer; gene expression; genome-wide association study
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.21902

Ovarian cancer (OC) is a common cancer in women and the leading cause of deaths from gynaecological malignancies in the world. In addition to the candidate gene approach to identify OC susceptibility genes, the genome-wide association study (GWAS) methods have reported new variants that are associated with OC risk. The minor allele of rs2072590 at 2q31 was associated with an increased OC risk, and was primarily significant for serous subtype. The OC risk-associated SNP rs2072590 lies in non-coding DNA downstream of
and upstream of
, and it tags SNPs in the
3' UTR. We think that the non-coding rs2072590 variant may contribute to OC susceptibility by regulating the gene expression of HOXD1 and HOXD3. In order to investigate this association, we performed a bioinformatics analysis by a functional annotation of rs2072590 variant using RegulomeDB (version 1.1), HaploReg (version 4.1), and PhenoScanner (version 1.1). Using HaploReg, we identified 19 genetic variants tagged by rs2072590 variant with with r
>= 0.8. Using RegulomeDB, we identified that three genetic variants are likely to affect TF binding + any motif + DNase Footprint + DNase peak. Other genetic variants are likely to affect TF binding + DNase peak. Using PhenoScanner (version 1.1), we identified that these 19 genetic variants could significantly regulate the expression of nearby genes, especially the HOXD1 and HOXD3 in human ovary tissue.